MCID: GRD007
MIFTS: 59

Grade Iii Astrocytoma

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Grade Iii Astrocytoma

MalaCards integrated aliases for Grade Iii Astrocytoma:

Name: Grade Iii Astrocytoma 12 52 15
Anaplastic Astrocytoma 12 52 58 54 17 71
Grade Iii Astrocytic Tumor 12
Astrocytoma, Anaplastic 6

Characteristics:

Orphanet epidemiological data:

58
anaplastic astrocytoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3078
MeSH 43 D001254
SNOMED-CT 67 55353007
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0334579
Orphanet 58 ORPHA251589
UMLS 71 C0334579

Summaries for Grade Iii Astrocytoma

NIH Rare Diseases : 52 Anaplastic astrocytoma is a rare, cancerous (malignant) type of brain tumor that arises from star-shaped brain cells called astrocytes. These cells surround and protect nerve cells in the brain and spinal cord. An anaplastic astrocytoma usually develops slowly over time, but may develop rapidly. Signs and symptoms vary depending on the location and size of the tumor and may include headaches, drowsiness, vomiting, and changes in personality or mental status. Some affected people have seizures , vision problems, weakness of the limbs, and/or coordination problems. Anaplastic astroctyomas usually occur sporadically but can be associated with a few rare, genetic disorders. Treatment may include surgery, radiation, and/or chemotherapy .

MalaCards based summary : Grade Iii Astrocytoma, also known as anaplastic astrocytoma, is related to glial tumor and oligoastrocytoma, and has symptoms including seizures, headache and motor manifestations. An important gene associated with Grade Iii Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Etoposide and Trioxsalen have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and breast, and related phenotypes are Reduced mammosphere formation and mortality/aging

Disease Ontology : 12 An astrocytoma that is characterized by cells with regular, round to oval nuclei.

Related Diseases for Grade Iii Astrocytoma

Diseases related to Grade Iii Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 437)
# Related Disease Score Top Affiliating Genes
1 glial tumor 33.8 PTEN OLIG2
2 oligoastrocytoma 31.6 MGMT IDH2 GFAP
3 meningioma, radiation-induced 31.5 S100A5 PCNA GFAP
4 juvenile pilocytic astrocytoma 31.4 PTEN OLIG2 MGMT GFAP CDK4
5 low-grade astrocytoma 31.4 TP53 CDKN2B CDKN2A
6 malignant glioma 31.3 VEGFA TP53 PTEN MMP2 MGMT MDM2
7 neurofibromatosis, type iv, of riccardi 31.2 TP53 PTEN PDGFRA
8 central neurocytoma 31.1 PCNA OLIG2 GFAP
9 fibrillary astrocytoma 31.0 TP53 PTEN PDGFRA OLIG2 MGMT IDH2
10 pleomorphic xanthoastrocytoma 30.9 TP53 MGMT GFAP
11 plexiform neurofibroma 30.9 TP53 PDGFRA CDKN2A
12 leukemia, acute lymphoblastic 3 30.8 TP53 PDGFRA CDKN2B CDKN2A
13 anaplastic oligodendroglioma 30.8 OLIG2 OLIG1 MGMT IDH2 CDKN2A
14 meningioma, familial 30.8 VEGFA TP53 PTEN PCNA OLIG2 MGMT
15 spinal cord astrocytoma 30.8 MGMT GFAP
16 arteriovenous malformation 30.8 VEGFA PTEN MMP2
17 hemangioblastoma 30.8 VEGFA GFAP EGFR
18 myelodysplastic syndrome 30.7 VEGFA TP53 PTEN MGMT MDM2 IDH2
19 brain glioma 30.7 VEGFA TP53 MGMT IDH2 GFAP EGFR
20 neurofibroma 30.7 VEGFA TP53 PTEN PDGFRA EGFR CDKN2A
21 leukemia, chronic myeloid 30.6 VEGFA TP53 PTEN PDGFRA EGFR CDKN2B
22 mixed glioma 30.6 TP53 PTEN PDGFRA OLIG2 MGMT IDH2
23 glioma 30.5 TP53 PTEN PDGFRA MMP2 MDM2 IDH2
24 medulloblastoma 30.5 VEGFA TP53 PTEN PDGFRA MGMT MDM2
25 renal cell carcinoma, nonpapillary 30.5 VEGFA TP53 PTEN PDGFRA MMP2 EGFR
26 brain cancer 30.4 VEGFA TP53 PTEN PDGFRA OLIG2 OLIG1
27 neuroblastoma 30.3 VEGFA TP53 PTEN MMP2 MDM2 GFAP
28 leukemia, acute myeloid 30.3 VEGFA TP53 PTEN PDGFRA MDM2 IDH2
29 gliosarcoma 30.2 VEGFA TP53 PTEN PDGFRA OLIG2 MMP2
30 glioblastoma multiforme 30.2 VEGFA TP53 PTEN PDGFRA MMP2 MGMT
31 oligodendroglioma 29.9 VEGFA TP53 PTEN PDGFRA PCNA OLIG2
32 glioma susceptibility 1 29.9 VEGFA TP53 PTEN PDGFRA OLIG2 MMP2
33 carcinosarcoma 10.8 TP53 PTEN EGFR
34 frontal lobe neoplasm 10.8 TP53 MGMT EGFR
35 oral leukoplakia 10.8 TP53 PCNA CDKN2A
36 ring chromosome 7 10.7 TP53 MDM2 CDK4
37 ring chromosome 10.7 TP53 MDM2 CDK4
38 cerebellum cancer 10.7 TP53 IDH2 GFAP
39 childhood oligodendroglioma 10.7 OLIG2 MGMT IDH2
40 vulvar intraepithelial neoplasia 10.7 TP53 CDKN2A
41 keratinizing squamous cell carcinoma 10.7 TP53 EGFR CDKN2A
42 vulvar seborrheic keratosis 10.7 PTEN CDKN2A
43 gastric liposarcoma 10.7 MDM2 CDK4
44 breast duct papilloma 10.7 PTEN IDH2
45 cervical mucinous adenocarcinoma 10.7 TP53 PTEN CDKN2A
46 bone squamous cell carcinoma 10.7 TP53 EGFR CDKN2A
47 third ventricle chordoid glioma 10.7 OLIG2 GFAP
48 malignant peritoneal mesothelioma 10.7 EGFR CDKN2A
49 actinic cheilitis 10.7 TP53 MDM2
50 mediastinum liposarcoma 10.7 MDM2 CDKN2A CDK4

Graphical network of the top 20 diseases related to Grade Iii Astrocytoma:



Diseases related to Grade Iii Astrocytoma

Symptoms & Phenotypes for Grade Iii Astrocytoma

UMLS symptoms related to Grade Iii Astrocytoma:


seizures, headache, motor manifestations, sensory manifestations

GenomeRNAi Phenotypes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CDK4 EGFR FOXM1 IDH2 MDM2 MMP2

MGI Mouse Phenotypes related to Grade Iii Astrocytoma:

45 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10.44 CDK4 CDKN2A CDKN2B DMBT1 EGFR FOXM1
2 cellular MP:0005384 10.43 CDK4 CDKN2A CDKN2B DMBT1 EGFR FOXM1
3 homeostasis/metabolism MP:0005376 10.41 CDK4 CDKN2A CDKN2B DMBT1 EGFR FOXM1
4 cardiovascular system MP:0005385 10.4 CDK4 CDKN2A EGFR FOXM1 GFAP IDH2
5 growth/size/body region MP:0005378 10.4 CDK4 CDKN2A EGFR GFAP MDM2 MMP2
6 immune system MP:0005387 10.4 CDK4 CDKN2A CDKN2B DMBT1 EGFR FOXM1
7 endocrine/exocrine gland MP:0005379 10.37 CDK4 CDKN2A CDKN2B EGFR FOXM1 MDM2
8 digestive/alimentary MP:0005381 10.35 CDK4 CDKN2A DMBT1 EGFR FOXM1 GFAP
9 neoplasm MP:0002006 10.35 CDK4 CDKN2A CDKN2B DMBT1 EGFR FOXM1
10 hematopoietic system MP:0005397 10.32 CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
11 nervous system MP:0003631 10.3 CDK4 CDKN2A EGFR GFAP MDM2 MGMT
12 muscle MP:0005369 10.27 CDK4 CDKN2A EGFR FOXM1 GFAP MDM2
13 embryo MP:0005380 10.25 CDK4 CDKN2A DMBT1 EGFR MDM2 PDGFRA
14 integument MP:0010771 10.25 CDK4 CDKN2A CDKN2B EGFR MDM2 OLIG1
15 craniofacial MP:0005382 10.16 CDK4 EGFR MDM2 MMP2 PDGFRA TP53
16 liver/biliary system MP:0005370 10.13 CDK4 CDKN2A EGFR FOXM1 MDM2 PTEN
17 no phenotypic analysis MP:0003012 10.13 CDKN2A CDKN2B EGFR MDM2 MGMT OLIG2
18 normal MP:0002873 10.1 CDK4 EGFR GFAP MDM2 MMP2 PDGFRA
19 limbs/digits/tail MP:0005371 10.08 EGFR IDH2 MDM2 PDGFRA PTEN TP53
20 renal/urinary system MP:0005367 9.97 CDK4 CDKN2B DMBT1 EGFR MDM2 PDGFRA
21 reproductive system MP:0005389 9.96 CDK4 CDKN2A CDKN2B EGFR MDM2 PCNA
22 pigmentation MP:0001186 9.91 CDK4 CDKN2A EGFR MDM2 PDGFRA PTEN
23 respiratory system MP:0005388 9.85 CDKN2A EGFR FOXM1 MGMT MMP2 OLIG2
24 skeleton MP:0005390 9.7 CDK4 CDKN2A EGFR IDH2 MDM2 MMP2
25 vision/eye MP:0005391 9.28 CDK4 CDKN2A EGFR GFAP MMP2 OLIG2

Drugs & Therapeutics for Grade Iii Astrocytoma

Drugs for Grade Iii Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 359)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 3 33419-42-0 36462
2
Trioxsalen Approved Phase 3 3902-71-4 5585
3
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
4
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
5
Donepezil Approved Phase 3 120014-06-4 3152
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
8
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
9
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
10
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
11
Flucytosine Approved, Investigational Phase 2, Phase 3 2022-85-7 3366
12
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
13
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
14
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
15
Carmustine Approved, Investigational Phase 3 154-93-8 2578
16
Bevacizumab Approved, Investigational Phase 3 216974-75-3
17
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
18
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
19
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
20
Histamine Approved, Investigational Phase 3 51-45-6 774
21
Cyproheptadine Approved Phase 3 129-03-3 2913
22
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
23
Semustine Experimental, Investigational Phase 3 13909-09-6
24 Mitolactol Investigational Phase 3 10318-26-0
25 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
26 Dianhydrogalactitol Investigational Phase 3 23261-20-3
27 Etoposide phosphate Phase 3
28 Immunosuppressive Agents Phase 3
29 Ether Phase 3
30 Hematoporphyrin Derivative Phase 3
31 Hematoporphyrins Phase 3
32 Photosensitizing Agents Phase 3
33 Dihematoporphyrin Ether Phase 3
34 Anesthetics Phase 3
35 Anesthetics, General Phase 3
36 Anesthetics, Inhalation Phase 3
37 Nootropic Agents Phase 3
38 Cholinergic Agents Phase 3
39 Cholinesterase Inhibitors Phase 3
40 Liver Extracts Phase 3
41 Cola Phase 3
42 Narcotics Phase 3
43 Analgesics, Opioid Phase 3
44 Adjuvants, Anesthesia Phase 3
45 Anesthetics, Intravenous Phase 3
46 Antiparasitic Agents Phase 3
47 Antiprotozoal Agents Phase 3
48 Antimitotic Agents Phase 3
49 Anticonvulsants Phase 3
50 Pharmaceutical Solutions Phase 3

Interventional clinical trials:

(show top 50) (show all 352)
# Name Status NCT ID Phase Drugs
1 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
3 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
4 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
5 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
6 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
7 EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
8 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
9 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
10 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
11 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
12 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
13 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
14 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
15 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
17 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Recruiting NCT03633552 Phase 3 Temozolomide
18 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
19 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
20 A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma Active, not recruiting NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
21 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
22 A Phase II/III Study of Non Small Cell Lung Cancer Patient With/Without Synchronous Oral Temozolomide Capsules Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost With Hippocampus Protection Not yet recruiting NCT03732482 Phase 2, Phase 3 Temozolomide capsules
23 A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Not yet recruiting NCT04105374 Phase 2, Phase 3 Extended Release Flucytosine;Temozolomide
24 Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study. Terminated NCT00761280 Phase 3 trabedersen;temozolomide;carmustine;lomustine
25 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
26 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
27 A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3) Terminated NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
28 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
29 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
30 A Phase II Study of Temozolomide in the Treatment of Recurrent Malignant Gliomas Unknown status NCT00004204 Phase 2 temozolomide
31 A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
32 A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
33 A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
34 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
35 Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups Unknown status NCT00313521 Phase 2 thiotepa
36 A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas Unknown status NCT00879437 Phase 2 Valproic acid;Bevacizumab
37 Pilot Study to Determine Therapeutic Response of Oral Capecitabine (Xeloda) in Recurrent High Grade Gliomas (HGGs) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria Completed NCT00717197 Phase 2 Capecitabine
38 Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma Completed NCT00006080 Phase 2 fenretinide
39 Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma) Completed NCT00003621 Phase 2 carmustine;cisplatin;etoposide
40 A Phase I/II Open Label, Single Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients With Recurrent High-Grade Glioma. Completed NCT00040573 Phase 1, Phase 2 131I-TM-601
41 Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Brain Tumors. Completed NCT00003457 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
42 A Phase I/II Trial Of MGI114 For Treatment Of Patients With Recurrent Malignant Gliomas Completed NCT00012038 Phase 1, Phase 2 irofulven
43 A Phase I/II Study of Col-3 Administered on a Continuous Daily Oral Schedule in Patients With Recurrent High-Grade Astrocytoma Completed NCT00004147 Phase 1, Phase 2 incyclinide
44 Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Completed NCT00859222 Phase 1, Phase 2 LBH589;bevacizumab
45 Phase II Study of Antineoplastons A10 and AS2-1 in Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
46 Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
47 Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma Completed NCT00003537 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
48 A Phase II Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme Completed NCT00921167 Phase 2 Bevacizumab/Irinotecan
49 A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma Completed NCT00002814 Phase 2 paclitaxel;topotecan hydrochloride
50 Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma Completed NCT00003470 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)

Search NIH Clinical Center for Grade Iii Astrocytoma

Genetic Tests for Grade Iii Astrocytoma

Anatomical Context for Grade Iii Astrocytoma

MalaCards organs/tissues related to Grade Iii Astrocytoma:

40
Brain, Spinal Cord, Breast, Bone, Lung, Endothelial, T Cells

Publications for Grade Iii Astrocytoma

Articles related to Grade Iii Astrocytoma:

(show top 50) (show all 2074)
# Title Authors PMID Year
1
Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. 54 61
20090216 2010
2
Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma. 54 61
19876867 2009
3
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. 54 61
19512898 2009
4
Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. 54 61
18795327 2009
5
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. 54 61
19346643 2009
6
Mutational inactivation of the nijmegen breakage syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations. 54 61
19151620 2009
7
Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. 54 61
19657395 2009
8
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. 54 61
18945611 2009
9
FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. 54 61
18974115 2008
10
PTEN signaling pathways in glioblastoma. 54 61
18836294 2008
11
Serum GFAP is a diagnostic marker for glioblastoma multiforme. 54 61
17998256 2007
12
Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. 54 61
17404569 2007
13
Concurrent EGFR amplification and TP-53 mutation in glioblastomas. 54 61
17907599 2007
14
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. 54 61
17721049 2007
15
Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. 54 61
17679463 2007
16
Molecular pathogenesis of pediatric astrocytic tumors. 54 61
17327574 2007
17
Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. 54 61
17415208 2007
18
Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. 54 61
16818615 2006
19
O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. 54 61
16849758 2006
20
Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas. 54 61
16614947 2006
21
Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. 54 61
16618782 2006
22
Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology. 54 61
16150117 2005
23
Apolipoprotein D expression in primary brain tumors: analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue. 54 61
16055749 2005
24
Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. 54 61
16030116 2005
25
Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma. 54 61
15973775 2005
26
Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. 54 61
15994925 2005
27
Apoptosis and proliferation: correlation with p53 in astrocytic tumours. 54 61
15981097 2005
28
Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. 54 61
15671553 2005
29
Brainstem gliomas--a clinicopathological study of 45 cases with p53 immunohistochemistry. 54 61
15659871 2004
30
Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. 54 61
12939468 2003
31
Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. 54 61
12968803 2003
32
Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. 54 61
12700122 2003
33
Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. 54 61
12777082 2003
34
Molecular genetic analysis of phosphatase and tensin homolog and p16 tumor suppressor genes in patients with malignant glioma. 54 61
15679305 2003
35
Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis. 54 61
12702589 2003
36
Recurrent astrocytic tumours--a study of p53 immunoreactivity and malignant progression. 54 61
12389885 2002
37
Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. 54 61
11958417 2002
38
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. 54 61
11683943 2001
39
Elevated levels of cathepsin B in human glioblastoma cell lines. 54 61
11494030 2001
40
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. 54 61
11504770 2001
41
[A case of glioblastoma associated with dissemination, secondary to intratumoral hemorrhage]. 54 61
11554096 2001
42
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. 54 61
11431323 2001
43
Characterisation of molecular alterations in microdissected archival gliomas. 54 61
11355303 2001
44
Comparison of cyclin A and MIB-1 expression in astrocytic tumors using image-based cell analysis system. 54 61
11277408 2001
45
Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. 54 61
11234878 2001
46
Promoter hypermethylation of the RB1 gene in glioblastomas. 54 61
11204276 2001
47
Regulation of the uPA gene in various grades of human glioma cells. 54 61
11115541 2001
48
Expression of hepatocyte growth factor and matrix metalloproteinase-2 in human glioma. 54 61
11517976 2001
49
Functional evaluation of p53 and PTEN gene mutations in gliomas. 54 61
11051241 2000
50
Molecular genetic analysis of archival gliomas using diagnostic smears. 54 61
11054184 2000

Variations for Grade Iii Astrocytoma

ClinVar genetic disease variations for Grade Iii Astrocytoma:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
2 TP53 NM_000546.5(TP53):c.844C>T (p.Arg282Trp)SNV Pathogenic/Likely pathogenic 12364 rs28934574 17:7577094-7577094 17:7673776-7673776
3 ATRX NM_000489.5(ATRX):c.5579A>G (p.Asn1860Ser)SNV Benign/Likely benign 11724 rs45439799 X:76856021-76856021 X:77600552-77600552

Expression for Grade Iii Astrocytoma

Search GEO for disease gene expression data for Grade Iii Astrocytoma.

Pathways for Grade Iii Astrocytoma

Pathways related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 VEGFA TP53 PTEN PDGFRA MDM2 EGFR
2
Show member pathways
13.72 VEGFA TP53 PDGFRA MMP2 MDM2 EGFR
3
Show member pathways
13.14 VEGFA TP53 MDM2 CDKN2B CDKN2A CDK4
4
Show member pathways
13.01 VEGFA TP53 PTEN PDGFRA MDM2 EGFR
5
Show member pathways
12.96 VEGFA TP53 PDGFRA MDM2 EGFR CDKN2A
6
Show member pathways
12.81 TP53 PTEN EGFR CDKN2B CDKN2A CDK4
7
Show member pathways
12.8 VEGFA TP53 PTEN PDGFRA PCNA MDM2
8
Show member pathways
12.74 TP53 PTEN PDGFRA MDM2 EGFR
9
Show member pathways
12.71 TP53 PCNA MGMT MDM2 CDK4
10
Show member pathways
12.64 VEGFA TP53 PTEN PDGFRA MDM2 EGFR
11
Show member pathways
12.59 TP53 PCNA MDM2 CDKN2B CDKN2A CDK4
12 12.58 VEGFA TP53 PTEN PDGFRA MMP2 MDM2
13 12.56 VEGFA TP53 PTEN PDGFRA MDM2 EGFR
14 12.53 TP53 PCNA MGMT MDM2 FOXM1 CDKN2A
15
Show member pathways
12.51 TP53 PTEN PDGFRA MMP2 MDM2 EGFR
16
Show member pathways
12.44 TP53 PDGFRA MDM2 EGFR
17
Show member pathways
12.43 TP53 PTEN MDM2 CDKN2A CDK4
18
Show member pathways
12.4 TP53 PTEN PCNA MDM2
19 12.38 TP53 PTEN CDKN2B CDKN2A CDK4
20 12.38 TP53 PCNA MDM2 CDKN2B CDKN2A CDK4
21
Show member pathways
12.36 TP53 CDKN2B CDKN2A CDK4
22 12.34 VEGFA TP53 MMP2 MDM2 EGFR
23 12.32 TP53 MDM2 CDKN2B CDKN2A CDK4
24
Show member pathways
12.27 TP53 PTEN MDM2 CDK4
25
Show member pathways
12.24 TP53 PTEN PDGFRA MDM2 EGFR CDK4
26 12.21 VEGFA TP53 MMP2 EGFR
27 12.16 VEGFA TP53 PTEN MDM2 EGFR CDK4
28
Show member pathways
12.15 PTEN MMP2 MDM2 EGFR
29
Show member pathways
12.12 PTEN MDM2 EGFR CDKN2B
30 12.07 TP53 PTEN PCNA MMP2 MDM2 EGFR
31 12.07 TP53 PTEN MDM2 FOXM1 CDKN2B CDKN2A
32 12.05 TP53 GFAP EGFR CDK4
33 12.03 TP53 PTEN MDM2 CDKN2A
34 11.98 TP53 PTEN PCNA MDM2 CDKN2A
35 11.92 TP53 PTEN CDKN2B CDK4
36 11.89 TP53 PCNA MDM2 CDK4
37 11.83 VEGFA PDGFRA OLIG2 OLIG1 GFAP
38
Show member pathways
11.75 TP53 MDM2 CDKN2A
39 11.75 TP53 MDM2 CDKN2A
40 11.74 TP53 PTEN PDGFRA EGFR
41 11.73 VEGFA TP53 MMP2 MDM2 CDKN2A
42 11.62 VEGFA TP53 MDM2 CDKN2A
43 11.61 PDGFRA MMP2 CDK4
44 11.6 TP53 PTEN MDM2
45 11.56 TP53 PDGFRA MMP2 EGFR CDKN2A
46 11.51 TP53 PCNA MDM2 CDK4
47 11.49 VEGFA PDGFRA EGFR
48 11.49 TP53 PTEN MDM2 CDKN2B CDK4
49 11.42 MMP2 FOXM1 CDK4
50 11.36 VEGFA TP53 MMP2 MDM2 EGFR CDKN2A

GO Terms for Grade Iii Astrocytoma

Cellular components related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.8 VEGFA TP53 S100A3 PTEN PDGFRA OLIG2
2 nucleus GO:0005634 9.5 TP53 S100A5 PTEN PDGFRA PCNA OLIG2

Biological processes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.13 VEGFA TP53 PDGFRA OLIG2 OLIG1 EGFR
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.1 VEGFA TP53 PCNA OLIG2 MDM2 FOXM1
3 viral process GO:0016032 10.01 TP53 PDGFRA PCNA MDM2 DMBT1
4 positive regulation of gene expression GO:0010628 10 VEGFA TP53 PTEN MDM2 CDKN2A
5 heart development GO:0007507 9.93 TP53 PTEN PCNA MDM2
6 negative regulation of apoptotic process GO:0043066 9.91 VEGFA TP53 PTEN MGMT MDM2 EGFR
7 response to drug GO:0042493 9.88 TP53 PTEN MGMT MDM2 CDK4
8 regulation of cell cycle GO:0051726 9.8 TP53 PTEN FOXM1 CDK4
9 epithelial cell differentiation GO:0030855 9.78 VEGFA PCNA DMBT1
10 negative regulation of neuron projection development GO:0010977 9.77 PTEN MDM2 GFAP
11 cellular response to hypoxia GO:0071456 9.76 VEGFA TP53 PTEN MDM2
12 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.74 TP53 PCNA MDM2
13 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.73 PTEN CDKN2B CDK4
14 cellular response to amino acid stimulus GO:0071230 9.72 PDGFRA MMP2 EGFR
15 positive regulation of fibroblast proliferation GO:0048146 9.69 PDGFRA EGFR CDK4
16 positive regulation of double-strand break repair GO:2000781 9.64 MGMT FOXM1
17 amyloid fibril formation GO:1990000 9.63 MDM2 CDKN2A
18 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 TP53 EGFR
19 cellular response to UV-C GO:0071494 9.58 TP53 MDM2
20 positive regulation of DNA repair GO:0045739 9.58 PCNA MGMT EGFR
21 negative regulation of cell aging GO:0090344 9.54 PTEN FOXM1
22 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.52 VEGFA TP53
23 positive regulation of cell proliferation GO:0008284 9.5 VEGFA PTEN PDGFRA MDM2 FOXM1 EGFR
24 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.46 PTEN CDKN2B CDKN2A CDK4
25 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.43 PTEN CDKN2B CDKN2A
26 cellular response to actinomycin D GO:0072717 9.37 TP53 MDM2
27 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.32 VEGFA PDGFRA
28 cellular response to reactive oxygen species GO:0034614 8.92 TP53 PDGFRA MMP2 EGFR

Molecular functions related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.87 VEGFA TP53 PTEN PCNA MDM2 GFAP
2 enzyme binding GO:0019899 9.65 TP53 PTEN PCNA MDM2 EGFR
3 protein kinase binding GO:0019901 9.43 TP53 PTEN FOXM1 EGFR CDKN2B CDKN2A
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.37 CDKN2B CDKN2A
5 disordered domain specific binding GO:0097718 9.33 TP53 MDM2 CDKN2A
6 platelet-derived growth factor receptor binding GO:0005161 8.8 VEGFA PTEN PDGFRA

Sources for Grade Iii Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....